Health Tennessee Oncology Study Shows Next-Generation KRAS Therapy Cuts Lung Cancer Death Risk by 44% October 26, 2026 Researchers at Tennessee Oncology contributed to a global Phase III clinical trial that revealed an investigational targeted therapy extended overall survival compared with currently approved treatments for patients with previously…
Health Experimental Lung Cancer Drug Shows 34% Reduction in Death Risk May 31, 2026 Breakthrough Results in Squamous Non-Small-Cell Lung Cancer An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a closely watched late-stage trial.…